A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-15. Anything still debated is marked as such rather than presented as settled.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
== Origins of pathology == Early understanding of the origins of diseases constitutes the earliest application of the scientific method to the field of medicine, a development which occurred in the Middle East during the Islamic Golden Age and in Western Europe during the Italian Renaissance. The Greek physician Hippocrates, the founder of scientific medicine, was the first to deal with the anatomy and the pathology of human spine. Galen developed an interest in anatomy from his studies of Herophilus and Erasistratus. The concept of studying disease through the methodical dissection and examination of diseased bodies, organs, and tissues may seem obvious today, but there are few if any recorded examples of true autopsies performed prior to the second millennium. Though the pathology of contagion was understood by Muslim physicians since the time of Avicenna (980–1037) who described it in The Canon of Medicine (c. 1020), the first physician known to have made postmortem dissections was the Arabian physician Avenzoar (1091–1161) who proved that the skin disease scabies was caused by a parasite, followed by Ibn al-Nafis (b. 1213) who used dissection to discover pulmonary circulation in 1242. In the 15th century, anatomic dissection was repeatedly used by the Italian physician Antonio Benivieni (1443–1502) to determine cause of death. Antonio Benivieni is also credited with having introduced necropsy to the medical field. Perhaps the most famous early gross pathologist was Giovanni Morgagni (1682–1771).
=== Sexual harassment allegation === Biologist Nancy Hopkins says when she was an undergraduate in the 1960s, Crick put his hands on her breasts during a lab visit. She described the incident: "Before I could rise and shake hands, he had zoomed across the room, stood behind me, put his hands on my breasts and said, 'What are you working on?'"
=== PHLWiki === In June 2006, Planet Half-Life began its own wiki project based on MediaWiki. The PHLWiki contained over a hundred articles dealing with fictional Half-Life characters, creatures and locations in an in-universe, encyclopedic form as well as real life articles on mods, player terminology and strategy guides. Before being announced publicly, most of the existing pages, particularly articles making up the fictional encyclopedia, were written by PHL staff writers. The PHLWiki has since shut down.
Sources: en.wikipedia.org
== Structure == The Lancet Group of Laboratories is a private pathology service based in Johannesburg, South Africa. It has over 100 reference laboratories and more than 250 branches in over 14 African countries. Tests provided include PCR and genetic tests for cancers and infectious diseases, histopathology, cytopathology, immunohistochemistry, testing for tuberculosis, microbiology, endocrinology, clinical chemistry, blood clotting, haematology, toxicology and tests relating to occupations.
A, B, C, D, E, F, G, I, J, K, L, P, Q1, R, S, T, U, V, Z1, Z2 Qi, Jianzhao; Wu, Jing; Kang, Shijie; Gao, Jingming; Hirokazu, Kawagishi; Liu, Hongwei; Liu, Chengwei (August 2024). "The chemical structures, biosynthesis, and biological activities of secondary metabolites from the culinary-medicinal mushrooms of the genus Hericium: a review". Chinese Journal of Natural Medicines. 22 (8): 676–698. doi:10.1016/S1875-5364(24)60590-X. ISSN 1875-5364. Retrieved 2026-01-30. J, K Kawagishi, Hirokazu; Masui, Ayano; Tokuyama, Shinji; Nakamura, Tomoyuki (September 2006). "Erinacines J and K from the mycelia of Hericium erinaceum". Tetrahedron. 62 (36): 8463–8466. Bibcode:2006Tetra..62.8463K. doi:10.1016/j.tet.2006.06.091. ISSN 0040-4020. Retrieved 2026-01-30. Spangenberg, E. T.; Moneypenny, A.; Bozzo, G. G.; Perreault, M. L. (2025-06-23). "Unveiling the role of erinacines in the neuroprotective effects of Hericium erinaceus: a systematic review in preclinical models". Frontiers in Pharmacology. 16 1582081. doi:10.3389/fphar.2025.1582081. ISSN 1663-9812. PMC 12230622. L Wei, Jing; Li, Jia-yao; Feng, Xi-long; Zhang, Yilin; Hu, Xuansheng; Hui, Heping; Xue, Xiaodong; Qi, Jianzhao (2023-08-31). "Unprecedented Neoverrucosane and Cyathane Diterpenoids with Anti-Neuroinflammatory Activity from Cultures of the Culinary-Medicinal Mushroom Hericium erinaceus". Molecules. 28 (17): 6380. doi:10.3390/molecules28176380. ISSN 1420-3049. PMID 37687209. Z1, Z2 Rupcic, Zeljka; Rascher, Monique; Kanaki, Sae; Köster, Reinhard; Stadler, Marc; Wittstein, Kathrin (2018-03-06).
==== Selective androgen receptor modulator-like activity ==== Although bicalutamide has been characterized as a silent antagonist of the AR in prostate tissue and other contexts, and despite its overall antiandrogenic profile, there is evidence that the drug may activate the AR to some degree in certain other tissues, such as muscle and bone among others. This would make bicalutamide a selective androgen receptor modulator (SARM), or a tissue-selective mixed agonist/antagonist or partial agonist of the AR, with antiandrogenic effects in some tissues and androgenic effects in other tissues, rather than a pure antiandrogen. This would be similar to certain other SARMs structurally related to bicalutamide, like enobosarm, which in animals have potent anabolic effects in muscle and bone but show partially agonistic or antagonistic effects in the prostate or seminal vesicles. Bicalutamide has been found to not oppose testosterone-induced increases in levator ani muscle weight in immature castrated male rats at doses of the drug (e.g., 0.08–2 mg/kg) that reduce or even completely block testosterone-induced prostate gland and seminal vesicle growth. In other studies, higher doses of bicalutamide (e.g., 10–30 mg/kg) reduced levator ani muscle weight (by ~40% or more) in gonadally intact male rats but had no effect on lean body mass (a surrogate of muscle mass), whereas castration reduced levator ani weight by around 70% and lean body mass by around 25%.
with sufficient accuracy for most practical purposes. In effect there is no need to define pKb separately from pKa, but it is done here as often only pKb values can be found in the older literature. For a hydrolyzed metal ion, Kb can also be defined as a stepwise dissociation constant
Sources: en.wikipedia.org
Affimer molecules, also known as adhiron, are small proteins that bind to target proteins with affinity in the nanomolar range. These engineered non-antibody binding proteins are designed to mimic the molecular recognition characteristics of monoclonal antibodies in different applications. These affinity reagents have been optimized to increase their stability, make them tolerant to a range of temperatures and pH, reduce their size, and to increase their expression in E.coli and mammalian cells.
== Society and culture == According to the parasite-stress theory of sociality, examined in a 2009 review by Nettle, several studies have reported associations between regional pathogen load and aspects of human social behavior. Proponents of the theory link higher pathogen load to smaller ethnic and religious group sizes, more restricted sexual behavior, stronger mate preferences for apparent health, higher fertility with reduced per-child parental investment, increased prevalence of polygyny, and greater collectivism relative to individualism. They attribute these patterns to strategies that may limit pathogen transmission or offset higher mortality. Nettle's review notes that alternative explanations exist for several of these associations, and that some of those alternative factors may themselves ultimately trace back to pathogen load. This body of research is largely correlational and is best understood as a proposed explanatory framework rather than an established causal mechanism.
Hitchens stated, "[an] unborn child seems to me to be a real concept. It's not a growth or an appendix. You can't say the rights question doesn't come up. I don't think a woman should be forced to choose, or even can be", and, "as a materialist, I think it has been demonstrated that an embryo is a separate body and entity". Showing a desire to recognise the unborn as a life, he also affirmed a need for the right to abortion, stating, "the second-best fallback solution, which may sometimes be desirable for other reasons, is termination of pregnancy... all thinking people recognise a painful conflict of rights and interest in this question". Hitchens opposed an overturning of Roe v. Wade and instead hoped for science to develop new solutions to unwanted pregnancies "that will make abortion more like a contraceptive procedure than a surgical one." He strongly criticized the encouragement of sexual abstinence within the anti-abortion movement of the Christian right, and the equating of contraceptives to abortion, as expressed by Mother Teresa and representatives of the Roman Catholic Church.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.